EpiAxis Therapeutics

Private

CanberraHealthcare & Life Scienceshttps://www.epiaxistherapeutics.com/

Last Round

Early Funding

Jun 9, 2022

Total Funding Raised

$890,000

Company Overview

EpiAxis Therapeutics is a biotechnology company that develops epigenetic-based treatments intended to prevent metastatic cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

epigenetic therapeuticsLSD1 inhibitorssynthetic peptideoncology drug discoverycancer stem cellsdrug repurposingAI-augmented drug discoveryPKC theta inhibitorsbiotech licensingin silico drug designprecision medicinedrug discovery pipelineAI drug discoverypharma partneringepigenetics

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

EpiAxis Therapeutics Comparables

Compare EpiAxis Therapeutics with similar companies based on industry and business-model similarity.

EpiAxis Therapeutics comparables — related companies by embedding similarity
Company	Similarity	Market Cap
Benz Sciences Inc.	77%
Merck & Co., Inc.	77%
Jubilant Pharmova Limited	76%

View all Comparables

EpiAxis Therapeutics Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Early Funding	Jun 9, 2022
VC Round	Dec 18, 2020
Seed	Feb 11, 2016

View all Funding Rounds

Key People

Founding team and executive leadership

Jeremy Chrisp

CEO

Executive Team

EpiAxis Therapeutics Investors

Notable investors and investment history

EpiAxis Therapeutics investors
Investor	Rounds
Sydney Angels	VC Round
ANU Connect Ventures	Seed
ACT Government	Seed

View all Investors

EpiAxis Therapeutics Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

EpiAxis Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about EpiAxis Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCanberra

Employee Range6

Year Founded2015

Last FundingJun 9, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.